1
|
Farr MA, Joshi TP, Fathy RA, Lewis DJ. Talimogene Laherparepvec for Advanced Stage Merkel Cell Carcinoma: Therapeutic Role and Immunologic Mechanisms. Skinmed 2023; 21:153-155. [PMID: 37634094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/28/2023]
Affiliation(s)
| | | | - Ramie A Fathy
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - Daniel J Lewis
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;
| |
Collapse
|
2
|
Singh R, Brown AM, Chan WH, Farr MA, Venkataraman S, Feldman SR. Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed? Expert Opin Biol Ther 2022; 22:1439-1441. [PMID: 35678210 DOI: 10.1080/14712598.2022.2088278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- Rohan Singh
- Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Alexandria M Brown
- Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Warren H Chan
- Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Morgan A Farr
- Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Sid Venkataraman
- Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Steven R Feldman
- Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.,Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.,Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| |
Collapse
|
3
|
Gray L, Kravitz E, Dillawn P, Farr MA, Schutt AK. UTILITY OF INSULIN CURVE CHALLENGE TESTING AND TESTOSTERONE AS INITIAL LABWORK FOR PCOS WORK UP. Fertil Steril 2022. [DOI: 10.1016/j.fertnstert.2022.08.548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
4
|
Joshi TP, Wang HY, Athukuri P, Bohac S, Farr MA, Hinson D, Kahla JA, Khalfe N, McBee DB, Stroh R, Walters N, Ren V. Biologic Therapies for the Management of Cutaneous Findings in Genodermatoses: A Review. Am J Clin Dermatol 2022; 23:673-688. [PMID: 35606649 DOI: 10.1007/s40257-022-00700-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/26/2022] [Indexed: 01/17/2023]
Abstract
Genodermatoses are genetically inherited dermatologic conditions. The management of cutaneous findings in genodermatoses is challenging, and first-line therapies, such as steroids and/or retinoids, are often inadequate. In recent years, research on the molecular basis of genodermatoses has led to the use of biologic therapies for intractable disease. Here, we review the evidence regarding the use of available biologic therapies for the management of dermatologic findings in genodermatoses. Biologic therapies appear to be promising therapeutic options for several recalcitrant genodermatoses, especially those with underlying immune dysregulation. However, not all genodermatoses are amenable to biologic therapies, and some have been shown to paradoxically worsen under treatment. Biologic therapies offer a novel avenue to target refractory genodermatoses. However, evidence supporting the use of biologic therapies in the management of genodermatoses is mostly limited to case reports and case series. Further studies are warranted to determine the safety and efficacy of biologic therapies for the management of cutaneous findings in genodermatoses.
Collapse
|
5
|
Singh R, Farr MA, Chan WH, Akkurt ZM, Huang WW, Strowd LC, Feldman SR. Beyond traditional meetings and webinars: identifying the educational preferences of practicing dermatologists. Dermatol Online J 2022; 28. [DOI: 10.5070/d328257405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Accepted: 05/10/2022] [Indexed: 11/08/2022] Open
|
6
|
Joshi TP, Farr MA, Hsiou DA, Nugent S, Fathy RA, Lewis DJ. Therapeutic targets for vaccination in polyomavirus-driven Merkel cell carcinoma. Dermatol Ther 2022; 35:e15580. [PMID: 35560970 DOI: 10.1111/dth.15580] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Revised: 04/03/2022] [Accepted: 04/19/2022] [Indexed: 11/03/2022]
Affiliation(s)
- Tejas P Joshi
- School of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Morgan A Farr
- School of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - David A Hsiou
- School of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Shannon Nugent
- Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA
| | - Ramie A Fathy
- School of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Daniel J Lewis
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
7
|
Joshi TP, Farr MA, Lewis DJ. Isotretinoin as Chemoprophylaxis for Cutaneous Malignancies in Muir-Torre Syndrome: A Novel Concept. Dermatol Ther 2022; 35:e15540. [PMID: 35477944 DOI: 10.1111/dth.15540] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2021] [Revised: 03/02/2022] [Accepted: 04/26/2022] [Indexed: 11/29/2022]
Affiliation(s)
- Tejas P Joshi
- School of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Morgan A Farr
- School of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Daniel J Lewis
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
8
|
Joshi TP, Farr MA, Lewis DJ. Epigenetic regulatory mechanisms of histone acetylation in the treatment of cutaneous squamous cell carcinoma. Expert Opin Ther Targets 2021; 25:1025-1026. [PMID: 34814792 DOI: 10.1080/14728222.2021.2010189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Cutaneous squamous cell carcinoma (cSCC) is the second most common malignancy; as such, novel systemic therapies are important for the treatment of locally advanced or metastatic disease. Histone deacetylase (HDAC) inhibitors have been increasingly studied in recent years as epigenome-targeted therapy for cSCC. HDACs inhibitors reduce tumorigenesis by blocking HDAC activity and creating a more relaxed chromatin structure, thus inducing gene expression by inhibiting deacetylation of transcription factors. In vitro experiments and in vivo mice studies have shown that HDAC inhibition halts cSCC pathogenesis. Ginsenoside 20(R)-Rg3 has been successfully employed to inhibit HDAC3 and thereby inhibit cSCC epithelial mesenchymal transition. Similarly, vorinostat has been found to blunt growth of human xenograft epidermoid cSCCs in highly immunosuppressed mice. Additionally, trichostatin A induces irreversible growth arrest in SCC cells, and MS-275 significantly reduces cSCC tumor burden in mice. These recent studies indicate that HDAC inhibitors represent a promising emerging therapy for cSCC.
Collapse
Affiliation(s)
- Tejas P Joshi
- School of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Morgan A Farr
- School of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Daniel J Lewis
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
9
|
Farr MA, Joshi TP, Lewis DJ. Resiquimod: a new topical immune-response modifier for the treatment of actinic keratosis. Expert Opin Emerg Drugs 2021; 26:433-434. [PMID: 34749552 DOI: 10.1080/14728214.2021.2004694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Resiquimod is a Toll-like receptor (TLR)-7 and TLR-8 agonist that, like imiquimod, belongs to the class of imidazoquinolines, small organic molecules with potent antiviral and anticancer activity. Resiquimod activates myeloid and plasmacytoid dendritic cells while also promoting release of cytokines as interleukin-6, tumor necrosis factor-α and interferon-γ more effectively than imiquimod. Given these immunologic effects, resiquimod is emerging as a new topical pharmacotherapy for actinic keratosis (AK). In the pivotal trial by Stockfleth et al. complete clinical clearance in all the resiquimod-treated arms was more significant than placebo varying from 56% to 74%. Partial clinical clearance, or disappearance of >75% of AKs, was also significantly higher in the resiquimod arms varying from 75% to 87%. Overall, resiquimod is a new molecule that remains a promising therapy for AK, although additional studies are needed to further evaluate its efficacy.
Collapse
Affiliation(s)
- Morgan A Farr
- School of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Tejas P Joshi
- School of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Daniel J Lewis
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
10
|
Kravitz E, Dillawn P, Farr MA, Schutt AK. UTILITY OF THE INSULIN CURVE IN ADDITION TO OGTT IN DETECTING HYPERINSULINEMIA IN PATIENTS WITH PCOS. Fertil Steril 2021. [DOI: 10.1016/j.fertnstert.2021.07.346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Farr MA, Joshi TP, Lewis DJ. Trends in cervical cancer screening from 2007 to 2016: association with decreased genital melanoma detection in females. Int J Dermatol 2021; 61:e326-e327. [PMID: 34403502 DOI: 10.1111/ijd.15859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Accepted: 07/30/2021] [Indexed: 11/28/2022]
Affiliation(s)
- Morgan A Farr
- ¹School of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Tejas P Joshi
- ¹School of Medicine, Baylor College of Medicine, Houston, TX, USA
| | - Daniel J Lewis
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
12
|
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has fundamentally transformed the landscape of providing dermatologic care. In an age of lockdowns and social distancing, teledermatology (TD) has emerged as a powerful tool to deliver remote care. Here, we review literature on TD use during the pandemic to evaluate the positives and negatives of TD implementation. We especially consider the reception of TD in underserved communities and the developing world as well as the ethico-legal challenges wrought by the burgeoning utilization of this new paradigm of care. The potential of TD to occupy a more prominent role in dermatologic care in a post-COVID-19 world is also discussed.
Collapse
Affiliation(s)
- Morgan A Farr
- School of Medicine, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA
| | - Madeleine Duvic
- Department of Dermatology, MD Anderson Cancer Center, Houston, TX, USA
| | - Tejas P Joshi
- School of Medicine, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
| |
Collapse
|